Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers

Trial Profile

A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs BHV-3500 (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 22 Oct 2018 Status changed from planning to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
    • 22 Oct 2018 According to a Biohaven Pharmaceutical media release, the first participant in this trial has been dosed with BHV-3500.The initiation of dosing follows Biohavens filing of an investigational new drug application (IND) for BHV-3500 in the treatment of migraine and receipt from FDA of authorization to proceed with the clinical investigation of this product candidate.
    • 12 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the trial is scheduled to begin in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top